Cargando…

Precision Behavioral Management (PBM) and Cognitive Control as a Potential Therapeutic and Prophylactic Modality for Reward Deficiency Syndrome (RDS): Is There Enough Evidence?

This brief commentary aims to provide an overview of the available and relatively new precision management of reward deficiencies manifested as substance and behavioral disorders. Current and future advances, concepts, and the substantial evidential basis of this potential therapeutic and prophylact...

Descripción completa

Detalles Bibliográficos
Autores principales:	Madigan, Margaret A., Gupta, Ashim, Bowirrat, Abdalla, Baron, David, Badgaiyan, Rajendra D., Elman, Igor, Dennen, Catherine A., Braverman, Eric R., Gold, Mark S., Blum, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9180535/ https://www.ncbi.nlm.nih.gov/pubmed/35681980 http://dx.doi.org/10.3390/ijerph19116395

Ejemplares similares

Should Reward Deficiency Syndrome (RDS) Be Considered an Umbrella Disorder for Mental Illness and Associated Genetic and Epigenetic Induced Dysregulation of Brain Reward Circuitry?
por: Blum, Kenneth, et al.
Publicado: (2022)

Hypothesizing That Pediatric Autoimmune Neuropsychiatric Associated Streptococcal (PANDAS) Causes Rapid Onset of Reward Deficiency Syndrome (RDS) Behaviors and May Require Induction of “Dopamine Homeostasis”
por: Blum, Kenneth, et al.
Publicado: (2022)

Reward Deficiency Syndrome (RDS): A Cytoarchitectural Common Neurobiological Trait of All Addictions
por: Blum, Kenneth, et al.
Publicado: (2021)

Genetic Addiction Risk Severity Assessment Identifies Polymorphic Reward Genes as Antecedents to Reward Deficiency Syndrome (RDS) Hypodopaminergia’s Effect on Addictive and Non-Addictive Behaviors in a Nuclear Family
por: Dennen, Catherine A., et al.
Publicado: (2022)

Reward Deficiency Syndrome (RDS) Surprisingly Is Evolutionary and Found Everywhere: Is It “Blowin’ in the Wind”?
por: Blum, Kenneth, et al.
Publicado: (2022)

Evidence for the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

DNA Directed Pro-Dopamine Regulation Coupling Subluxation Repair, H-Wave(®) and Other Neurobiologically Based Modalities to Address Complexities of Chronic Pain in a Female Diagnosed with Reward Deficiency Syndrome (RDS): Emergence of Induction of “Dopamine Homeostasis” in the Face of the Opioid Crisis
por: Bajaj, Anish, et al.
Publicado: (2022)

Pro-Dopamine Regulator – (KB220) to Balance Brain Reward Circuitry in Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2017)

How to Combat the Global Opioid Crisis
por: Dennen A., Catherine, et al.
Publicado: (2023)

A Review of DNA Risk Alleles to Determine Epigenetic Repair of mRNA Expression to Prove Therapeutic Effectiveness in Reward Deficiency Syndrome (RDS): Embracing “Precision Behavioral Management”
por: Blum, Kenneth, et al.
Publicado: (2021)

Neurogenetic and Epigenetic Aspects of Cannabinoids
por: Dennen, Catherine A., et al.
Publicado: (2022)

Molecular Genetic Testing in Reward Deficiency Syndrome (RDS): Facts and Fiction
por: Blum, Kenneth, et al.
Publicado: (2015)

Future Newborns with Opioid-Induced Neonatal Abstinence Syndrome (NAS) Could Be Assessed with the Genetic Addiction Risk Severity (GARS) Test and Potentially Treated Using Precision Amino-Acid Enkephalinase Inhibition Therapy (KB220) as a Frontline Modality Instead of Potent Opioids
por: Ceccanti, Mauro, et al.
Publicado: (2022)

Hypothesizing in the Face of the Opioid Crisis Coupling Genetic Addiction Risk Severity (GARS) Testing with Electrotherapeutic Nonopioid Modalities Such as H-Wave Could Attenuate Both Pain and Hedonic Addictive Behaviors
por: Gupta, Ashim, et al.
Publicado: (2022)

“Preaddiction” construct and reward deficiency syndrome: genetic link via dopaminergic dysregulation
por: Blum, Kenneth, et al.
Publicado: (2022)

“TO BE OR NOT TO BE” GWAS Ends the Controversy about the DRD2 Gene as a Determinant of Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2023)

Theorizing the Role of Dopaminergic Polymorphic Risk Alleles with Intermittent Explosive Disorder (IED), Violent/Aggressive Behavior and Addiction: Justification of Genetic Addiction Risk Severity (GARS) Testing
por: Modestino, Edward Justin, et al.
Publicado: (2022)

Proposing a “Brain Health Checkup (BHC)” as a Global Potential “Standard of Care” to Overcome Reward Dysregulation in Primary Care Medicine: Coupling Genetic Risk Testing and Induction of “Dopamine Homeostasis”
por: Braverman, Eric R., et al.
Publicado: (2022)

Coupling Neurogenetics (GARS™) and a Nutrigenomic Based Dopaminergic Agonist to Treat Reward Deficiency Syndrome (RDS): Targeting Polymorphic Reward Genes for Carbohydrate Addiction Algorithms
por: Blum, Kenneth, et al.
Publicado: (2015)

Researching Mitigation of Alcohol Binge Drinking in Polydrug Abuse: KCNK13 and RASGRF2 Gene(s) Risk Polymorphisms Coupled with Genetic Addiction Risk Severity (GARS) Guiding Precision Pro-Dopamine Regulation
por: Blum, Kenneth, et al.
Publicado: (2022)

Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape
por: Blum, Kenneth, et al.
Publicado: (2017)

Beyond Mor: Can Induction of Dopamine Homeostasis Along with Electrotherapy Attenuate the Opioid Crisis?
por: Blum, Kenneth, et al.
Publicado: (2023)

Introducing Precision Addiction Management of Reward Deficiency Syndrome, the Construct That Underpins All Addictive Behaviors
por: Blum, Kenneth, et al.
Publicado: (2018)

Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management”
por: Blum, Kenneth, et al.
Publicado: (2022)

Statistical Validation of Risk Alleles in Genetic Addiction Risk Severity (GARS) Test: Early Identification of Risk for Alcohol Use Disorder (AUD) in 74,566 Case–Control Subjects
por: Blum, Kenneth, et al.
Publicado: (2022)

Genetic Addiction Risk and Psychological Profiling Analyses for “Preaddiction” Severity Index
por: Blum, Kenneth, et al.
Publicado: (2022)

Neurological correlates of brain reward circuitry linked to opioid use disorder (OUD): Do homo sapiens acquire or have a reward deficiency syndrome?
por: Gold, Mark S., et al.
Publicado: (2020)

Generational Association Studies of Dopaminergic Genes in Reward Deficiency Syndrome (RDS) Subjects: Selecting Appropriate Phenotypes for Reward Dependence Behaviors
por: Blum, Kenneth, et al.
Publicado: (2011)

Positive Clinical Outcomes for Severe Reported Pain Using Robust Non-Addictive Home Electrotherapy—A Case-Series
por: Bajaj, Anish, et al.
Publicado: (2023)

Pro-Dopamine Regulator (KB220) A Fifty Year Sojourn to Combat Reward Deficiency Syndrome (RDS): Evidence Based Bibliography (Annotated)
por: Kenneth, Blum, et al.
Publicado: (2018)

Can We Combat Reward Deficiency Behaviors (RDS) including Substance Use Disorder (SUD) through Genetic Risk Screening coupled with Precision Pro-Dopamine Regulation by Algorithmic matched Polymorphic Allelic Risks
por: Blum, Kenneth, et al.
Publicado: (2019)

Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary
por: Blum, Kenneth, et al.
Publicado: (2008)

Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
por: Blum, Kenneth, et al.
Publicado: (2015)

Invited Expert Opinion- Bioinformatic and Limitation Directives to Help Adopt Genetic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Required Analytic Evidence to Induce Dopamine Homeostatsis
por: Blum, Kenneth, et al.
Publicado: (2023)

Metheamphetamine for Children: Are We Over or Under Dosing?
por: Blum, Kenneth, et al.
Publicado: (2023)

Hypothesizing Nutrigenomic-Based Precision Anti-Obesity Treatment and Prophylaxis: Should We Be Targeting Sarcopenia Induced Brain Dysfunction?
por: Blum, Kenneth, et al.
Publicado: (2021)

Genetic Addiction Risk Score (GARS): Molecular Neurogenetic Evidence for Predisposition to Reward Deficiency Syndrome (RDS)
por: Blum, Kenneth, et al.
Publicado: (2014)

A Novel Precision Approach to Overcome the “Addiction Pandemic” by Incorporating Genetic Addiction Risk Severity (GARS) and Dopamine Homeostasis Restoration
por: Blum, Kenneth, et al.
Publicado: (2021)

KB220Z™ a Pro-Dopamine Regulator Associated with the Protracted, Alleviation of Terrifying Lucid Dreams. Can We Infer Neuroplasticity-induced Changes in the Reward Circuit?
por: McLaughlin, Thomas, et al.
Publicado: (2016)

Neurogenetics and Epigenetics of Loneliness
por: Bowirrat, Abdalla, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17f37ut1el4ok72pfuuublu88k